Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Manuel Ramos-Vasquez"'
Autor:
Kevin M Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori A Goldstein, Stephen KL Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H Arce-Salinas, Etienne GC Brain, Eun Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vasquez, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steven Shak, Priyanka Sharma, Danika Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel Hortobagyi
Publikováno v:
Cancer Research. 82:GS2-07
Background: We previouslyreported that invasive disease-free survival (IDFS), the primary outcome, and distantdisease-free survival (DDFS), a secondary outcome, differed by menopausalstatus in a pre-specified analysis. Here,we report updates on IDFS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a95210de8eeb612c414b52ca70dc2d77
https://doi.org/10.1158/1538-7445.sabcs21-gs2-07
https://doi.org/10.1158/1538-7445.sabcs21-gs2-07
Autor:
Ana Lluch, Priyanka Sharma, Daniel F. Hayes, Jean-Marc Ferrero, Suzette Delaloge, Lajos Pusztai, Lori J. Goldstein, Miguel Martín, Emilio Alba, S Shak, Subkhbinder Dhesy-Thind, Manuel Ramos Vasquez, Stephen Chia, Gabriel N. Hortobagyi, Edith A. Perez, Funda Meric-Bernstam, Claudia Arce-Salinas, Julie R. Gralow, Nancy Lin, Kyung Hae Jung, Anne F. Schott, In Hae Park, William E. Barlow, Kevin Kalinsky, Danika L. Lew, Jieling Miao, Jean-Yves Pierga, Kathy S. Albain, Priya Rastogi, Debu Tripathy, Miguel Gil, Manuel Ruiz Borrego, Etienne Brain
Publikováno v:
Cancer Research. 81:GS3-00
Funding: Supported by National Cancer Institute grants U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868, U10CA180863; and in part by Susan G. Komen for the Cure® Research Program, The Hope Foundation for Cancer Research, Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64f5bd06a75125628f5a5767d255f239
https://doi.org/10.1158/1538-7445.sabcs20-gs3-00
https://doi.org/10.1158/1538-7445.sabcs20-gs3-00
Autor:
J. Thaddeus Beck, Pantelia Roussou, Suzette Delaloge, Petr Krivorotko, Patrick Urban, Manuel Ruiz Borrego, Arlene Chan, Roberto Hegg, Norberto Batista López, Qamar J. Khan, Joyce O'Shaughnessy, Alexey Manikhas, Mario Campone, Mikhail Shtivelband, Cristian Massacesi, Miguel Martín, Emmanuelle di Tomaso, Manuel Ramos Vasquez, Luc Dirix
Publikováno v:
Molecular Cancer Therapeutics. 14:A166-A166
Introduction: Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer (BC) is associated with tumor growth and resistance to anticancer therapies, including paclitaxel (PAC). Combined treatment with the pan-Class I PI3K inhibitor bup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3eb22fb0496b58277fd8298a17268f8
https://doi.org/10.1158/1535-7163.targ-15-a166
https://doi.org/10.1158/1535-7163.targ-15-a166